Epithalon — Research Overview
Chemical Name: Ala-Glu-Asp-Gly (AEDG tetrapeptide) Also Known As: Epitalon, Epithalone, AEDG peptide Molecular Weight: 390.35 g/mol Molecular Formula: C14H22N4O9 Structure: Synthetic tetrapeptide of four amino acids — alanine, glutamic acid, aspartic acid, and glycine — bound through alpha-peptide bonds Origin: Synthesized based on the amino acid composition of Epithalamin, a polypeptide extract derived from the bovine pineal gland. Epithalon was confirmed to be present in physiological human pineal gland extract in 2017. Category: Pineal gland-derived tetrapeptide / geroprotective research peptide / telomerase activator
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is Epithalon?
Epithalon is a synthetic tetrapeptide developed by researchers at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, primarily under the direction of Professor Vladimir Khavinson. It was synthesized based on the amino acid composition of Epithalamin — a polypeptide preparation derived from the pineal glands of bovine animals — and subsequently identified as a naturally occurring constituent of physiological human pineal gland extract in 2017, confirming its endogenous origin.
The pineal gland is a small endocrine organ located between the two hemispheres of the brain that plays a central role in circadian rhythm regulation through the production of melatonin. Melatonin secretion by the pineal gland declines significantly with age, and this decline has been associated in research with disrupted circadian regulation, reduced antioxidant capacity, immune dysregulation, and accelerated aging biology.
Epithalon has been studied across in vitro cell systems, in vivo animal models, and in limited human clinical studies across a broad range of biological endpoints including telomere dynamics, telomerase activity, melatonin regulation, antioxidant enzyme activity, immune function, lifespan extension, retinal protection, and tumor incidence. It has been studied over a period of more than 25 years making it one of the more extensively characterized short synthetic peptides in the geroscience research literature.
An important context note for researchers: the large majority of Epithalon research — estimated at more than 80% of published studies — has originated from a single research group led by Professor Khavinson and colleagues, primarily at the St. Petersburg Institute of Bioregulation and Gerontology. A significant proportion of these publications are in Russian and not available in English translation. Independent replication of the key findings from external laboratories has been limited, though studies from independent groups including recent publications from Western institutions have begun to confirm some core findings particularly in the area of telomere biology. This context is presented not to dismiss the research but to allow researchers to accurately assess the generalizability and replication status of the evidence base.
Mechanism of Action
Epithalon does not act through a single fully characterized receptor pathway. Its mechanisms of action have been studied through multiple approaches and several distinct but potentially interconnected activities have been identified in the published literature.
Telomerase activation and telomere elongation: The most widely studied mechanism of Epithalon involves activation of telomerase — the enzyme responsible for adding telomeric repeat sequences to chromosome ends. Telomerase is suppressed in most human somatic cells, contributing to progressive telomere shortening with each cell division. Published cell culture research has demonstrated that Epithalon upregulates hTERT (the catalytic subunit of telomerase) mRNA expression, increases telomerase enzyme activity, and produces measurable telomere elongation in human fibroblast and other cell lines. These findings were first reported by Khavinson and colleagues in 2003 and have more recently been independently confirmed by researchers in the United Kingdom using quantitative PCR and immunofluorescence analysis published in 2025.
Direct DNA interaction: Epithalon’s molecular size of 390 daltons is small enough to allow direct interaction with DNA. Computational and experimental studies have identified specific complementary interactions between Epithalon and DNA base sequences (specifically ATTTC motifs), suggesting possible direct epigenetic regulation of gene expression including chromatin remodeling and modification of heterochromatin.
Melatonin synthesis regulation: Epithalon has been shown to influence melatonin production and circadian rhythm entrainment, though findings are not entirely consistent across all model systems. Restoration of melatonin and cortisol circadian rhythms has been reported in aged rhesus monkeys (old primates aged 20 to 26 years), where Epithalon treatment restored the disturbed neuroendocrine regulation characteristic of aging primates toward patterns seen in younger animals.
Antioxidant enzyme enhancement: Epithalon and its precursor Epithalamin have been shown to increase the activity of antioxidant enzymes including superoxide dismutase, glutathione peroxidase, and glutathione-S-transferase in aging rats. Published research indicates that pineal peptide preparations can possess antioxidant properties exceeding those of melatonin through mechanisms that include both direct antioxidant activity and stimulation of endogenous antioxidant enzyme systems.
Immune modulation: Epithalon has been shown to alter mRNA levels of interleukin-2 and modulate the mitogenic activity of murine thymocytes. T and B cell-mediated immunity in adult and old mice has been reported to be stimulated by pineal peptide preparations, suggesting an immunomodulatory role consistent with the broader geroprotective profile.
Mitochondrial effects: Recent research has demonstrated that Epithalon reduces intracellular reactive oxygen species, enhances mitochondrial membrane potential, increases mitochondrial DNA copy number, and reduces apoptosis in oocyte aging models — pointing to a role in mitochondrial quality maintenance.
Published Research
Study 1 — Telomerase Activation and Telomere Elongation in Human Somatic Cells
Authors: Khavinson VK, Bondarev IE, Butyugov AA Year: 2003 Journal: Bulletin of Experimental Biology and Medicine PMID: 12937682 Full text: https://pubmed.ncbi.nlm.nih.gov/12937682/
This foundational cell culture study reported the first characterization of Epithalon’s effects on telomerase activity and telomere length in human somatic cells. The experiment used telomerase-positive HeLa cell cultures and human fetal lung fibroblasts.
Epithalon-treated fibroblasts demonstrated high telomere lengths during the G1 phase of the cell cycle as confirmed by the telomere repeat amplification (TRAP) protocol.
Telomerase activity was significantly upregulated in Epithalon-treated cells.
A follow-up study by the same group in 2004 reported that Epithalon-treated human fetal fibroblast cultures continued to divide beyond the 44th passage, surpassing the Hayflick limit of approximately 34 passages observed in untreated control cultures — suggesting that Epithalon-induced telomerase activation was sufficient to extend the replicative potential of normal human cells in vitro.
The authors proposed that this telomerase-activating activity could explain most of the geroprotective effects attributed to Epithalon.
Study 2 — Independent Replication: Telomere Extension in Human Cell Lines (2025)
Authors: Al-Dulaimi S, Thomas R, Matta S, Roberts T Year: 2025 Journal: Biogerontology PMID: 40908429 Full text: https://pubmed.ncbi.nlm.nih.gov/40908429/
This independently conducted study from researchers outside Russia represents a significant development in the Epithalon literature, providing the first independent replication of core telomere findings using modern quantitative molecular methods. Breast cancer cell lines (21NT and BT474) and normal epithelial and fibroblast cells were treated with Epithalon and analyzed by qPCR and immunofluorescence.
In normal healthy mammalian cells, Epithalon produced dose-dependent telomere length extension through upregulation of hTERT mRNA expression and telomerase enzyme activity, independently confirming the original Khavinson findings from 2003.
In cancer cell lines, significant telomere length extension also occurred but through ALT (Alternative Lengthening of Telomeres) activation rather than primarily through hTERT upregulation, with only minor ALT activity observed in normal cells — demonstrating a mechanistic distinction between Epithalon’s effects in normal versus cancer cells.
This study is notable because it represents independent international confirmation of core Epithalon telomere biology using rigorous modern molecular tools, addressing one of the primary limitations of the previous research base.
Study 3 — Lifespan Extension and Biomarkers of Aging in SHR Mice
Authors: Anisimov VN, Khavinson VK, Popovich IG, Zabezhinski MA, Alimova IN et al. Year: 2003 Journal: Biogerontology (Springer) Full text: https://link.springer.com/article/10.1023/A:1025114230714
This study examined the effects of lifelong Epithalon treatment on aging biomarkers, lifespan, and spontaneous tumor incidence in female SHR mice. Animals received subcutaneous injections of 1.0 micrograms per mouse (approximately 30 to 40 micrograms per kilogram) on 5 consecutive days every month from age 3 months until natural death. 54 mice per group.
Epithalon treatment did not significantly influence food consumption or mean body weight.
Epithalon slowed down the age-related switching-off of estrous function, demonstrating geroprotective effects on reproductive aging.
The frequency of chromosome aberrations in bone marrow cells was decreased by 17.1% (P less than 0.05) in Epithalon-treated animals, indicating antimutagenic activity.
The maximum lifespan of Epithalon-treated mice was increased by 24.1% compared to controls in this study cohort.
Study 4 — Drosophila Lifespan and Antioxidant Effects
Authors: Anisimov VN, Mylnikov SV, Oparina TI, Khavinson VK Year: 1997 Journal: Mechanisms of Ageing and Development PMID: 9226628 Full text: https://pubmed.ncbi.nlm.nih.gov/9226628/
This comparative study examined the effects of Epithalamin and melatonin on the lifespan of Drosophila melanogaster and on the intensity of lipid peroxidation and antioxidant enzyme activity, providing mechanistic context for the observed longevity effects.
Both Epithalamin and melatonin increased lifespan in Drosophila, with effects attributable to stimulation of melatonin synthesis and modulation of free radical processes.
Pineal peptide preparations possessed antioxidant properties that in some cases exceeded those of melatonin, attributed to both direct antioxidant effects and stimulation of endogenous antioxidant enzyme systems.
Subsequent research published in Mechanisms of Ageing and Development in 2000 reported that Epithalon specifically increased the lifespan of Drosophila melanogaster by up to 16% and that this effect required 16,000-fold lower concentrations than melatonin to achieve comparable mean lifespan extension — suggesting a highly potent and dose-efficient mechanism of action at the biological level.
Study 5 — Circadian Rhythm Restoration in Aged Primates
Authors: Khavinson VKh, Goncharova ND, Lapin BA Year: 2001 Journal: Neuroendocrinology Letters Referenced via: https://pubmed.ncbi.nlm.nih.gov/12374906/
This study examined the effect of Epithalon on melatonin production and cortisol circadian rhythms in senescent rhesus monkeys (aged 20 to 26 years) compared to young adults (aged 6 to 8 years), directly testing whether Epithalon could restore the disturbed neuroendocrine regulation characteristic of aged primates.
Epithalon restored disturbed neuroendocrine regulation in senescent monkeys, bringing melatonin production patterns and cortisol circadian rhythms closer to those observed in young adult controls.
Old animals showed significantly reduced melatonin production compared to young controls. Epithalon treatment produced a statistically significant improvement in melatonin output in old monkeys (P less than 0.001 compared to control old subjects).
The cortisol circadian rhythm — which is characteristically disrupted in aging — was partially restored by Epithalon treatment in older animals.
These findings support the hypothesis that Epithalon’s geroprotective effects operate in part through restoration of pineal neuroendocrine function and circadian biology, which have broad downstream effects on immune function, metabolism, and tissue maintenance.
Study 6 — Comprehensive Review: Geroprotective and Neuroendocrine Properties (2025)
Authors: Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L Year: 2025 Journal: International Journal of Molecular Sciences (PMC) PMID: 40141333 Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/
This comprehensive 2025 peer-reviewed review from researchers in Poland synthesized 25 years of Epithalon research across in vitro, in vivo, and in silico studies. It represents the most current comprehensive analysis of the Epithalon literature available and was conducted by researchers independent of the Khavinson group.
The review confirmed that Epithalon exerts a direct influence on melatonin synthesis, alters IL-2 mRNA levels, modulates murine thymocyte mitogenic activity, and enhances the activity of multiple enzymes including AChE, BuChE, and telomerase across the published literature.
Significant geroprotective and neuroendocrine effects were confirmed across the body of evidence including antioxidant, neuroprotective, and antimutagenic activities.
The review acknowledged that despite extensive study, it remains uncertain whether the characterized mechanisms are the sole mechanisms of action, reflecting the genuine complexity of Epithalon’s biological profile.
The authors identified the 2025 independent telomere replication study (Al-Dulaimi et al.) as a significant advance in independently confirming core Epithalon biology.
Additional Research Areas Associated With Epithalon
The following additional biological activities have been reported in the published literature. The evidence base and level of independent replication varies across each area.
Retinal protection: Epithalon prolonged functional integrity of the eye retina in Campbell rats with hereditary retinitis pigmentosa. A human clinical observation reported positive clinical effects in 90% of retinitis pigmentosa cases in a treated group, though this report is limited and has not been independently replicated.
Tumor incidence research: Multiple preclinical studies in cancer-prone rodent models reported that Epithalon decreased spontaneous tumor incidence and reduced the development of mammary tumors in HER-2/neu transgenic mice. Because Epithalon activates telomerase — an enzyme also associated with cancer cell replication — the oncological implications of Epithalon require careful investigation. The preclinical data suggesting reduced tumor incidence in these models does not resolve the theoretical concern about telomerase activation in the context of oncogenesis.
Chromosome protection: Studies in senescence-accelerated mice reported that Epithalon treatment significantly reduced the incidence of chromosomal aberrations, consistent with its proposed antimutagenic activity.
Cardiovascular and metabolic effects in clinical observations: Russian clinical studies involving elderly adults with accelerated aging due to cardiovascular disease reported geroprotective effects over multi-year follow-up periods. These studies involved the Epithalamin preparation rather than synthetic Epithalon specifically and have not been independently replicated.
An Important Note on the Research Landscape
As noted in the introduction, the large majority of Epithalon research originates from a single research group in Russia. This does not make the research invalid — it represents a sustained multi-decade scientific program — but it means that the generalizability and reproducibility of findings across independent laboratories is limited. The 2025 independent telomere confirmation study from Al-Dulaimi et al. represents an important step toward broader independent validation of core findings.
The telomerase activation mechanism also raises a theoretical concern that deserves explicit acknowledgment: telomerase is reactivated in most human cancers and is one of the hallmarks of cancer cell immortality. Activating telomerase in somatic cells could theoretically have oncogenic implications, though the preclinical data from Epithalon studies has not demonstrated increased tumor formation. This question remains open and is one of the central reasons why rigorous human clinical trials would be necessary before any conclusions about the risk-benefit profile of Epithalon in human subjects could be drawn.
Epithalon is approved for human use in Russia. It is not approved by the FDA for any indication in the United States.
Current Research Status
Epithalon has an extensive preclinical research history spanning more than 25 years and has been studied in limited human clinical settings primarily in Russia. It is not approved by the FDA for any indication and has not completed formal Western regulatory clinical trial programs. Recent independent replication of telomere biology findings from a UK-based laboratory represents a meaningful step toward broader scientific validation.
The following remain to be established through independent research and formal clinical trials:
Large-scale randomized controlled human clinical trial data from independent institutions.
Long-term safety profile in human populations.
Resolution of the telomerase activation and oncological risk question in human subjects.
Human pharmacokinetic data including bioavailability, half-life, and tissue distribution.
Optimal dosing, timing, and administration route for specific research applications.
Reconstitution Note
Epithalon is a tetrapeptide compound. Bacteriostatic water is the standard reconstitution solvent for this compound in laboratory research settings. Epithalon dissolves readily in bacteriostatic water without requiring acidic solvents. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the Epithalon product page: https://roguecompounds.com/product/epithalon/